JMJohn Donald Marra

John Donald Marra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


John Donald Marra has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • Patrizia Chiusolo

    Department of Laboratory and Hematological Sciences Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy

    6 shared publications
  • Alberto Fresa

    Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori-IRCCS-Fondazione ‘G. Pascale’, Via Mariano Semmola 49, 80131 Naples, Italy

    3 shared publications
  • Federica Sorà

    Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Rome, Italy

    3 shared publications
  • Gessica Minnella

    Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia Fondazione Policlinico Universitario “A. Gemelli” IRCCS Rome Italy

    3 shared publications
  • Dimitrios Mougiakakos

    Health campus for Inflammation, Immunity and Infection (GCI3), Otto-von-Guericke University of Magdeburg

    2 shared publications
  • Elisabetta Metafuni

    Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia Fondazione Policlinico Universitario “A. Gemelli” IRCCS Rome Italy

    2 shared publications

Latest Publications

  • CAR‐T from cord blood in a patient with Ph+ acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplantation

    by John Donald Marra, Eugenio Galli, Sabrina Giammarco, Elisabetta Metafuni, Gessica Minnella, Federica Fosso, Sara Marietti, Simona Sica, Federica Sorà, Patrizia Chiusolo

    While there is intense interest in the production of allogeneic CAR‐T cells from umbilical cord units, little is known about the reactivity and persistence of CAR‐T cells of umbilical origin. We report the case of a patient at our hematological center with multiple relapsing Ph+ B‐ALL, notably a Blinatunomab non‐responder, who underwent therapy with Brexucabtagene Autoleucel following relapse on Ponatinib post‐allogeneic hematopoietic stem cell transplantation. The patient achieved a rapid CAR‐T expansion and durable remission presenting in good clinical conditions 6 months post‐CAR‐T infusion, without manifestations of graft‐versus‐host disease. The case report provides insight into the reactivity and persistence of CAR‐T cells of umbilical origin, confirming the potential promise of allogeneic umbilical cord‐derived CAR‐T cells.


  • Open Access

    Unveiling the signaling network of FLT3-ITD AML improves drug sensitivity prediction

    by Sara Latini, Veronica Venafra, Giorgia Massacci, Valeria Bica, Simone Graziosi, Giusj Monia Pugliese, Marta Iannuccelli, Filippo Frioni, Gessica Minnella, John Donald Marra, et al.

    Summary Currently, the identification of patient-specific therapies in cancer is mainly informed by personalized genomic analysis. In the setting of acute myeloid leukemia (AML), patient-drug treatment matching fails in a subset of patients harboring atypical internal tandem duplications (ITDs) in the tyrosine kinase domain of the FLT3 gene. To address this unmet medical need, here we develop a systems-based strategy that integrates multiparametric analysis of crucial signaling pathways, patient-specific genomic and transcriptomic data with a prior-knowledge signaling network using a Boolean-based formalism. By this approach, we derive personalized predictive models describing the signaling landscape of AML FLT3-ITD positive cell lines and patients. These models enable us to derive mechanistic insight into drug resistance mechanisms and suggest novel opportunities for combinatorial treatments. Interestingly, our analysis reveals that the JNK kinase pathway plays a crucial role in the tyrosine kinase inhibitor response of FLT3-ITD cells through cell cycle regulation. Finally, our work shows that patient-specific logic models have the potential to inform precision medicine approaches.

  • Open Access

    Unveiling the signaling network of FLT3-ITD AML improves drug sensitivity prediction

    by Sara Latini, Veronica Venafra, Giorgia Massacci, Valeria Bica, Simone Graziosi, Giusj Monia Pugliese, Marta Iannuccelli, Filippo Frioni, Gessica Minnella, John Donald Marra, et al.

    Summary: Currently, the identification of patient-specific therapies in cancer is mainly informed by personalized genomic analysis. In the setting of acute myeloid leukemia (AML), patient-drug treatment matching fails in a subset of patients harboring atypical internal tandem duplications (ITDs) in the tyrosine kinase domain of the FLT3 gene. To address this unmet medical need, here we develop a systems-based strategy that integrates multiparametric analysis of crucial signaling pathways, patient-specific genomic and transcriptomic data with a prior-knowledge signaling network using a Boolean-based formalism. By this approach, we derive personalized predictive models describing the signaling landscape of AML FLT3-ITD positive cell lines and patients. These models enable us to derive mechanistic insight into drug resistance mechanisms and suggest novel opportunities for combinatorial treatments. Interestingly, our analysis reveals that the JNK kinase pathway plays a crucial role in the tyrosine kinase inhibitor response of FLT3-ITD cells through cell cycle regulation. Finally, our work shows that patient-specific logic models have the potential to inform precision medicine approaches.

  • Effect of HLA mismatch on post-transplant infections in allogeneic hematopoietic stem cell transplantation with PTCy-based GvHD prophylaxis

    by J. D. Marra, E. Galli, S. Giammarco, P. Chiusolo, E. Metafuni, F. Sora, L. Laurenti, I. Innocenti, F. Autore, M. A. Limongiello, et al.


  • Open Access

    Effect of HLA Mismatch on Post-Transplant Infections in Allogeneic Hematopoietic Stem Cell Transplantation with PTCy-Based GvHD Prophylaxis

    by John Marra, Eugenio Galli, Sabrina Giammarco, Patrizia Chiusolo, Elisabetta Metafuni, Federica Sora, Luca Laurenti, Idanna Innocenti, Francesco Autore, Maria Assunta Limongiello, et al.

    The aim of the study was to assess the risk of infections in the first 100 days in patients grafted from haploidentical donors (HAPLO) (n=116) or HLA-matched donors (MATCHED) (Related, n=29; unrelated n=39): all patients received graft-versus-host disease (GvHD) prophylaxis with post-transplant cyclophosphamide (PTCy), mycophenolate, and cyclosporine. The two groups had comparable age, intensity of conditioning, and disease status; the stem cell source was bone marrow for HAPLO and peripheral blood for MATCHED transplants. HAPLO patients had an increased risk of bloodstream infections (BSI) (HR 2.54; 95% CI 1.39-4.62; p=0.002), in particular gram-positive BSI (HR 4.42; 95% CI 1.57-12.5; p=0.005). HAPLO patients also had increased CMV infection/reactivation (HR 3.51; 95% CI 1.79-6.87; p<0.001) and a trend for increased invasive fungal infections (HR 1.80; 95% CI 0.90-3.57; p=0.10) and EBV infection/reactivation (HR 2.07; 95% CI 0.44-9.70; p=0.35). Overall, post-transplant infections were more likely to result in infection-related mortality in HAPLO grafts (p=0.03). In this single-center study, patients with HAPLO grafts had an increased risk of BSI and CMV infection/reactivation and a trend for increased IFI and EBV infection/reactivation, compared with MATCHED grafts. These findings call for diligent monitoring of infections in patients undergoing a HAPLO transplant.

  • Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma

    by Eugenio Galli, Federica Sorà, Stefan Hohaus, Silvia Bellesi, Francesco Autore, Elisabetta Metafuni, Idanna Innocenti, John Marra, Alberto Fresa, Maria Assunta Limongiello, et al.